Insider Trades61 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Sell | OCUL | Pravin Dugel | — | 100,184 | $8.94 | $2.0B | -45.44% | +43.98% | $895.6K | +0.00% | — | Stalk |
| Jun 3, 2026 | Sell | OCUL | Nadia Waheed | Chief Medical Officer | 14,828 | $8.27 | $2.0B | -45.44% | +43.98% | $122.6K | -4.71% | — | Stalk |
| May 26, 2026 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 1,858 | $8.20 | $2.0B | -45.44% | +43.98% | $15.2K | -0.56% | — | Stalk |
| May 26, 2026 | Sell | OCUL | Peter Kaiser | Chief Development Officer | 2,967 | $8.20 | $2.0B | -45.44% | +43.98% | $24.3K | -1.10% | — | Stalk |
| May 26, 2026 | Sell | OCUL | Jeffrey S. Heier | Chief Scientific Officer | 3,018 | $8.20 | $2.0B | -45.44% | +43.98% | $24.7K | -0.93% | — | Stalk |
| May 26, 2026 | Sell | OCUL | Pravin Dugel | — | 810,548 | $0.21 | $2.0B | -45.44% | +43.98% | $173.5K | -0.64% | — | Stalk |
| Apr 9, 2026 | Sell | OCUL | Pravin Dugel | — | 789,392 | $9.30 | $2.0B | -45.44% | +43.98% | $7.3M | +0.00% | — | Stalk |
| Feb 23, 2026 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 1,759 | $8.28 | $2.0B | -45.44% | +43.98% | $14.6K | -0.53% | — | Stalk |
| Feb 23, 2026 | Sell | OCUL | Peter Kaiser | Chief Development Officer | 2,810 | $8.28 | $2.0B | -45.44% | +43.98% | $23.3K | -1.03% | — | Stalk |
| Feb 23, 2026 | Sell | OCUL | Jeffrey S. Heier | Chief Scientific Officer | 3,057 | $8.28 | $2.0B | -45.44% | +43.98% | $25.3K | -0.94% | — | Stalk |
| Feb 23, 2026 | Sell | OCUL | Pravin Dugel | — | 20,056 | $8.28 | $2.0B | -45.44% | +43.98% | $166.1K | -0.66% | — | Stalk |
| Feb 20, 2026 | Sell | OCUL | Nadia Waheed | Chief Medical Officer | 3,510 | $7.74 | $2.0B | -45.44% | +43.98% | $27.2K | -1.10% | — | Stalk |
| Feb 12, 2026 | Sell | OCUL | Nadia Waheed | Chief Medical Officer | 7,863 | $9.04 | $2.0B | -45.44% | +43.98% | $71.1K | -2.41% | — | Stalk |
| Feb 12, 2026 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 10,348 | $9.04 | $2.0B | -45.44% | +43.98% | $93.5K | -3.02% | — | Stalk |
| Feb 12, 2026 | Sell | OCUL | Donald Notman | Chief Operating Officer | 11,446 | $9.04 | $2.0B | -45.44% | +43.98% | $103.5K | -3.03% | — | Stalk |
| Feb 12, 2026 | Sell | OCUL | Pravin Dugel | — | 124,882 | $9.04 | $2.0B | -45.44% | +43.98% | $1.1M | -3.95% | — | Stalk |
| Feb 2, 2026 | Sell | OCUL | Donald Notman | Chief Operating Officer | 11,490 | $8.82 | $2.0B | -45.44% | +43.98% | $101.4K | -1.49% | — | Stalk |
| Nov 24, 2025 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 1,878 | $12.04 | $2.0B | -45.44% | +43.98% | $22.6K | -0.67% | — | Stalk |
| Nov 24, 2025 | Sell | OCUL | Peter Kaiser | Chief Development Officer | 3,007 | $12.02 | $2.0B | -45.44% | +43.98% | $36.1K | -1.55% | — | Stalk |
| Nov 24, 2025 | Sell | OCUL | Jeffrey S. Heier | Chief Scientific Officer | 3,469 | $12.04 | $2.0B | -45.44% | +43.98% | $41.8K | -1.39% | — | Stalk |
| Nov 24, 2025 | Sell | OCUL | Pravin Dugel | — | 119,038 | $1.98 | $2.0B | -45.44% | +43.98% | $235.1K | -0.56% | — | Stalk |
| Nov 5, 2025 | Sell | OCUL | Namrata Saroj | Chief Business Officer | 25,865 | $10.74 | $2.0B | -45.44% | +43.98% | $277.8K | -12.93% | — | Stalk |
| Oct 8, 2025 | Sell | OCUL | Todd Anderman | Chief Legal Officer | 11,132 | $12.34 | $2.0B | -45.44% | +43.98% | $137.4K | -11.28% | — | Stalk |
| Oct 2, 2025 | Sell | OCUL | Peter Kaiser | Chief Development Officer | 9,653 | $11.03 | $2.0B | -45.44% | +43.98% | $106.5K | -4.73% | — | Stalk |
| Oct 2, 2025 | Sell | OCUL | Jeffrey S. Heier | Chief Scientific Officer | 10,502 | $11.04 | $2.0B | -45.44% | +43.98% | $115.9K | -4.04% | — | Stalk |
| Sep 9, 2025 | Sell | OCUL | Pravin Dugel | — | 99,508 | $12.76 | $2.0B | -45.44% | +43.98% | $1.3M | +0.00% | — | Stalk |
| Sep 2, 2025 | Sell | OCUL | Donald Notman | — | 1,066 | $12.43 | $2.0B | -45.44% | +43.98% | $13.3K | -0.34% | — | Stalk |
| Aug 25, 2025 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 1,885 | $12.04 | $2.0B | -45.44% | +43.98% | $22.7K | -0.67% | — | Stalk |
| Aug 25, 2025 | Sell | OCUL | Peter Kaiser | Chief Development Officer | 3,011 | $12.04 | $2.0B | -45.44% | +43.98% | $36.3K | -1.45% | — | Stalk |
| Aug 25, 2025 | Sell | OCUL | Jeffrey S. Heier | Chief Scientific Officer | 3,063 | $12.04 | $2.0B | -45.44% | +43.98% | $36.9K | -1.16% | — | Stalk |
| Aug 25, 2025 | Sell | OCUL | Pravin Dugel | — | 21,494 | $12.04 | $2.0B | -45.44% | +43.98% | $258.8K | -0.66% | — | Stalk |
| Jun 2, 2025 | Sell | OCUL | Nadia Waheed | Chief Medical Officer | 13,861 | $8.05 | $2.0B | -45.44% | +43.98% | $111.6K | -6.28% | — | Stalk |
| May 23, 2025 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 1,862 | $7.17 | $2.0B | -45.44% | +43.98% | $13.4K | -0.66% | — | Stalk |
| May 23, 2025 | Sell | OCUL | Peter Kaiser | Chief Development Officer | 2,974 | $7.17 | $2.0B | -45.44% | +43.98% | $21.3K | -1.42% | — | Stalk |
| May 23, 2025 | Sell | OCUL | Jeffrey S. Heier | Chief Scientific Officer | 3,024 | $7.18 | $2.0B | -45.44% | +43.98% | $21.7K | -1.14% | — | Stalk |
| May 23, 2025 | Sell | OCUL | Pravin Dugel | — | 21,219 | $7.18 | $2.0B | -45.44% | +43.98% | $152.4K | -0.60% | — | Stalk |
| Apr 28, 2025 | Sell | OCUL | Pravin Dugel | — | 500,722 | $8.13 | $2.0B | -45.44% | +43.98% | $4.1M | +0.00% | — | Stalk |
| Feb 24, 2025 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 1,895 | $6.84 | $2.0B | -45.44% | +43.98% | $13.0K | -0.66% | — | Stalk |
| Feb 24, 2025 | Sell | OCUL | Peter Kaiser | Chief Development Officer | 3,009 | $6.87 | $2.0B | -45.44% | +43.98% | $20.7K | -1.41% | — | Stalk |
| Feb 24, 2025 | Sell | OCUL | Jeffrey S. Heier | Chief Scientific Officer | 3,061 | $6.87 | $2.0B | -45.44% | +43.98% | $21.0K | -1.14% | — | Stalk |
| Feb 24, 2025 | Sell | OCUL | Pravin Dugel | — | 21,475 | $6.87 | $2.0B | -45.44% | +43.98% | $147.5K | -0.61% | — | Stalk |
| Jan 31, 2025 | Sell | OCUL | Donald Notman | — | 17,420 | $7.82 | $2.0B | -45.44% | +43.98% | $136.2K | -4.19% | — | Stalk |
| Nov 25, 2024 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 1,814 | $9.00 | $2.0B | -45.44% | +43.98% | $16.3K | -1.03% | — | Stalk |
| Nov 25, 2024 | Sell | OCUL | Peter Kaiser | Chief Development Officer | 2,897 | $9.01 | $2.0B | -45.44% | +43.98% | $26.1K | -1.34% | — | Stalk |
| Nov 25, 2024 | Sell | OCUL | Jeffrey S. Heier | Chief Scientific Officer | 2,948 | $9.01 | $2.0B | -45.44% | +43.98% | $26.6K | -1.08% | — | Stalk |
| Nov 25, 2024 | Sell | OCUL | Pravin Dugel | — | 20,680 | $9.01 | $2.0B | -45.44% | +43.98% | $186.3K | -2.55% | — | Stalk |
| Aug 23, 2024 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 1,832 | $9.02 | $2.0B | -45.44% | +43.98% | $16.5K | -1.03% | — | Stalk |
| Aug 23, 2024 | Sell | OCUL | Pravin Dugel | — | 20,880 | $9.02 | $2.0B | -45.44% | +43.98% | $188.3K | -2.51% | — | Stalk |
| May 23, 2024 | Sell | OCUL | Sanjay Nayak | Chief Strategy Officer | 2,274 | $5.84 | $2.0B | -45.44% | +43.98% | $13.3K | -1.26% | — | Stalk |
| May 23, 2024 | Sell | OCUL | Pravin Dugel | — | 21,626 | $5.79 | $2.0B | -45.44% | +43.98% | $125.2K | -2.53% | — | Stalk |
| Feb 5, 2024 | Sell | OCUL | Christopher G White | Chief Business Officer | 5,910 | $4.86 | $2.0B | -45.44% | +43.98% | $28.7K | -2.37% | — | Stalk |
| Feb 5, 2024 | Sell | OCUL | Philip C. Strassburger | General Counsel | 6,029 | $4.86 | $2.0B | -45.44% | +43.98% | $29.3K | -1.76% | — | Stalk |
| Feb 5, 2024 | Sell | OCUL | Donald Notman | Chief Financial Officer | 6,212 | $4.86 | $2.0B | -45.44% | +43.98% | $30.2K | -1.61% | — | Stalk |
| Feb 5, 2024 | Sell | OCUL | Rabia Gurses Ozden | Chief Medical Officer | 6,346 | $4.86 | $2.0B | -45.44% | +43.98% | $30.8K | -1.77% | — | Stalk |
| Feb 5, 2024 | Sell | OCUL | Antony C. Mattessich | President and CEO | 19,642 | $4.86 | $2.0B | -45.44% | +43.98% | $95.5K | -1.70% | — | Stalk |
| Jan 31, 2024 | Sell | OCUL | Christopher G White | Chief Business Officer | 5,147 | $4.95 | $2.0B | -45.44% | +43.98% | $25.5K | -5.43% | — | Stalk |
| Jan 31, 2024 | Sell | OCUL | Donald Notman | Chief Financial Officer | 6,433 | $4.95 | $2.0B | -45.44% | +43.98% | $31.8K | -4.40% | — | Stalk |
| Jan 31, 2024 | Sell | OCUL | Philip C. Strassburger | General Counsel | 6,831 | $4.95 | $2.0B | -45.44% | +43.98% | $33.8K | -5.89% | — | Stalk |
| Jan 31, 2024 | Sell | OCUL | Rabia Gurses Ozden | Chief Medical Officer | 7,764 | $4.95 | $2.0B | -45.44% | +43.98% | $38.4K | -7.72% | — | Stalk |
| Jan 31, 2024 | Sell | OCUL | Antony C. Mattessich | President and CEO | 18,338 | $4.95 | $2.0B | -45.44% | +43.98% | $90.8K | -4.11% | — | Stalk |
| Aug 30, 2023 | Buy | OCUL | Antony C. Mattessich | President and CEO | 6,500 | $3.81 | $2.0B | -45.44% | +43.98% | $24.8K | — | — | Stalk |